Strokes and diabetes

Practical Diabetes International

Volumn 22, Issue 6, 2005, Pages 215-221

  Harrow, Craig J ^a   Fisher, Miles ^b  

^a WESTERN INFIRMARY   (United Kingdom)

^b GLASGOW ROYAL INFIRMARY   (United Kingdom)

Author keywords

ACE inhibitors; Diabetes; Hypertension; Statins; Strokes

Indexed keywords

ACETYLSALICYLIC ACID; ANTIDIABETIC AGENT; ANTITHROMBOCYTIC AGENT; ATENOLOL; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CAPTOPRIL; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FELODIPINE; GLITAZONE DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INDAPAMIDE; INSULIN; LOSARTAN; METFORMIN; PERINDOPRIL; PLACEBO; PRAVASTATIN; RAMIPRIL; SIMVASTATIN; SULFONYLUREA;

CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DIABETES MELLITUS; DOPPLER FLOWMETRY; DRUG ANTAGONISM; DRUG EFFICACY; ECHOGRAPHY; GLYCEMIC CONTROL; HUMAN; HYPERTENSION; MONOTHERAPY; MORTALITY; NON INVASIVE PROCEDURE; OUTCOME ASSESSMENT; PATHOGENESIS; PREVALENCE; PRIMARY PREVENTION; REVIEW; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SCREENING TEST; SECONDARY PREVENTION;

EID: 34347258926     PISSN: 13578170     EISSN: 1528252X     Source Type: Journal    
DOI: 10.1002/pdi.820     Document Type: Review

References (45)

1. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001; 286: 1195-1200.
2. Tuomilheto J, Rastenyte D, Jousilahti P, et al.. Diabetes mellitus as a risk factor for death from Stroke. Stroke 1996; 27: 210-215.
3. Stamler J, Vaccaro O, Neaton JD, et al. Diabetes, other factors, and 12yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care 1993; 16: 434-444.
4. Haheim LL, Holme I, Hjermann I, et al. Nonfasting serum glucose and the risk of fatal Stroke in diabetic and nondiabetic subjects. Stroke 1995; 26: 774-777.
5. Kuusito J, Mykkanen L, Pyorala K, et al. Non-insulin dependant diabetes and its metabolic control are important predictors of Stroke in elderly subjects. Stroke 1994; 25: 1157-1164.
6. Barrett-Connor E, Shaw KT. Diabetes mellitus: an independent risk factor for Stroke. Am J Epidemiol 1988; 128: 116-123.
7. Lehto S, Ronnemaa T, Pyorala K, et al. Predictors of Stroke in middle-aged patients with non-insulin dependant diabetes. Stroke 1996; 27: 63-68.
8. D'Agostino RB, Wolf PA, Belanger AJ, et al. Stroke risk profile: adjustment for antihypertensive medication. Stroke 1994; 25: 40-43.
9. Davis PH, Dambrosia JM, Schoenberg BS. Risk factors for ischaemic Stroke: a prospective study in Rochester, Minnesota. Ann Neurol 1987; 22: 319-327.
10. Burchfield CM, Curb JD, Rodriguez BL, et al. Glucose intolerance and 22-year Stroke incidence: the Honolulu heart program. Stroke 1994; 25: 951-957.
11. Laing SP, Swerdlow AJ, Carpenter LM, et al.. Mortality from cerebrovascular disease in a cohort of 23000 patients with insulin treated diabetes. Stroke 2003; 34: 418-421.
12. Kiers L, Davis SM, Larkins R, et al. Stroke topography and outcome in relation to hyperglycaemia and diabetes. J Neurol Neurosurg Psychiatry 1992; 55: 263-270.
13. Pulsinelli WA, Levy DE, Sigsbee B, et al. Increased damage after ischaemic stroke in patients with hyperglycaemia with or without established diabetes mellitus. Am J Med 1983; 74: 540-544.
14. Oppenheimer SM, Hoffbrand BI, Oswald GA, et al. Diabetes mellitus and early mortality from Stroke. BMJ 1985; 291: 1014-1015.
15. Asplund K, Hagg E, Helmers C, et al. The natural history of Stroke in diabetic patients. Acta Med Scand 1980; 207: 417-424.
16. Horowitz SH, Zito JL, Donnarumma R, et al.. Clinical-radiographic correlations within the first five hours of cerebral infarction. Acta Neurol Scand 1982; 86: 207-214.
17. Peress NS, Kane WC, Aronson SM. Central nervous system findings in a tenth decade autopsy population. Prog Brain Res 1973; 40: 473-483.
18. Mast H, Thompson JLP, Lee SH, et al. Hypertension and diabetes mellitus as determinants of multiple lacunar infarcts. Stroke 1995; 26: 30-33.
19. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329: 977-986.
20. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352: 837-853.
21. UK Prospective Diabetes Study (UKPDS) Group. Effect of intensive blood-glucose control with metformin on complications in over-weight patients with type 2 diabetes (UKPDS 34). Lancet 1998; 352: 854-865.
22. Marx N, Sukhova G, Murphy C, et al. Macrophages in human atheroma contain PPARgamma: differentiation-dependent peroxisomal proliferator-activated receptor gamma (PPARgamma) expression and reduction of MMP-9 activity through PPARgamma activation in mononuclear phagocytes in vitro. Am J Pathol 1998; 153: 17-23.
23. Watanabe Y, Sunayama S, Shimada K, et al. Troglitazone improves endothelial dysfunction in patients with insulin resistance. J Atheroscler Thromb 2000; 7: 159-163.
24. Marx N, Mackman N, Schonbeck U, et al. PPARalpha activators inhibit tissue factor expression and activity in human monocytes. Circulation 2001; 103: 213-219.
25. Wolf PA, Belanger AJ, D'Agostino RB. Management of risk factors. Neurologic Clinics 1992; 10: 177-191.
26. Law MR, Frost CD, Wald NJ. By how much does dietary sodium reduction lower blood pressure? III - Analysis of data from trials of salt reduction. BMJ 1991; 302: 819-824 [erratum appears in BMJ 1991; 302: 939].
27. Hypertension in Diabetes Study Group. HDS 1: Prevalence of hypertension in newly presenting type 2 diabetic patients and the association with risk factors for cardio-vascular and diabetic complications. J Hypertens 1993; 11: 309-317.
28. Prescott-Clarke P, Primatesta P (eds). Health survey for England 1995. London: HMSO, 1997.
29. Harris MI, Cowie CC, Stern MP, et al. (eds). Diabetes in America, 2nd edn. Washington, DC: National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 1995.
30. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
31. Hansson L, Zanchetti A, Carruthers SG, et al. Effects of intensive blood pressure lowering and low dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. Lancet 1998; 351: 1755-1762.
32. Heart Outcomes Prevention Evaluation Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE sub-study. Lancet 2000; 355: 253-259.
33. Dahlöf B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002; 359: 995-1003.
34. Chapman N, Huxley R, Anderson C, et al. Effects of perindopril based blood pressure lowering regimen on the risk of recurrent stroke according to stroke subtype and medical history. The Progress Trial. Stroke 2004; 35: 116-121.
35. Berthet K, Neal BC, Chalmers JP, et al. Reduction in risks of recurrent stroke in patients with and without diabetes. The PROGRESS trial. Blood Pressure 2004; 13: 7-13.
36. Keech A, Colquhoun D, Best J, et al. Secondary prevention of cardiovascular events with long term pravastatin in patients with diabetes or impaired fasting glucose. Diabetes Care 2003; 26: 2713-2721.
37. Goldberg RB, Mellies MJ, Sacks FM et al; for the CARE Investigators. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels. Subgroup analyses in the Cholesterol And Recurrent Events (CARE) Trial. Circulation 1998; 98: 2513-2519.
38. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360: 7-22.
39. Collins R, Armitage J, Parish S, et al; for the Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003; 361: 2005-2016.
40. Colhoun HM, Betteridge DJ, Durrington PN, et al. on behalf of the CARDS investigators. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004; 364: 685-696.
41. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy. I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994; 308: 81-106.
42. Antithrombotic Trialists' Collaboration. Collaboration meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and Stroke in high risk patients. BMJ 2002; 324: 71-86.
43. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329-1339.
44. Bhatt D, Marso S, Hirsch A, et al. Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. Am J Cardiol 2002; 90: 625-628.
45. Diener H-C, Bogousslavsky J, Brass LM, et al; on behalf of the MATCH Investigators. Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo controlled trial. Lancet 2004; 364: 331-337.